Peipert, John Devin
Shaunfield, Sara
Kaiser, Karen
Moreno, Patricia I.
Fox, Rina S.
Kircher, Sheetal
Mohindra, Nisha
Ip, Edward
Zhao, Fengmin
Wagner, Lynne
Cella, David
Funding for this research was provided by:
National Cancer Institute (5U01CA233169, 5U01CA233169, 5U01CA233169, 5U01CA233169, 5U01CA233169)
Article History
Received: 2 May 2022
Accepted: 30 November 2022
First Online: 16 December 2022
Change Date: 24 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00520-023-07953-7
Declarations
:
: All 3 study’s protocols were sent to the Northwestern University IRB. Studies 1 and 3 were determined to be non-human subject research (STU#s 00203656, 00210027, respectively). Study 2 was determined to be human subject research (#STU00102531).
: All participants gave written or oral informed consent prior to beginning study activities.
: Consent for publication was included in informed consent.
: The authors declare no competing interests.
: Patient-reported approaches to capturing treatment tolerability in cancer clinical trials are needed. The FACT GP5 item, “I am bothered by side effects of treatment,” is an understandable, relevant, flexible way to capture overall side effect impact efficiently.